ERBB2 and cancer: Several genes included in clinical prognostic assays for HR+/HER2- cancer, such as the Oncotype DX Breast Recurrence Score test, were identified as differentially expressed between the two ancestral groups (Fig. 2B, Additional file 5: Table S4).